EDIT vs MET · rev $32.3M vs P/E 13, $52.16B cap
Editas Medicine Inc (EDIT) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
MET does not have a complete income-statement cache yet.
EDIT currently screens at market cap $375.2M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the EDIT and MET stock pages for the full models.
Not investment advice.